ClinicalTrials.gg
CompletedNCT04747197Updated Jul 19, 2023

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

A Phase 1 interventional study of EYP-1901 in Wet Age-related Macular Degeneration, sponsored by EyePoint Pharmaceuticals, Inc.. Completed at 11 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
405th of 491
17 · median 55
Started
2021
with 27 others
Phase 1
91 of 645
10 open now
Registered
473rd of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 405th largest by enrollment of the 491 interventional ones that give a count, is one of 28 that started in 2021, is one of 91 in phase 1, and was the 473rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age Related Macular Degeneration (wAMD)

03

Conditions studied

  • Wet Age-related Macular Degeneration

Keywords

  • wAMD
  • EYP-1901
  • EyePoint
  • DAVIO
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with wet Age-Related Macular Degeneration (wAMD), in the study eye.
  • Subject must have received ≥3 prior injections with the same anti-VEGF product: bevacizumab, ranibizumab, or aflibercept) in the 6 months prior to the Screening Visit, in the study eye.
  • Demonstrated response to the intravitreal anti-vascular endothelial growth factor (VEGF) treatment in the study eye.
  • Best-corrected visual acuity (BCVA) using ETDRS charts of 25 letters (20/320 Snellen equivalent) to 85 letters (20/20 Snellen equivalent).

Exclusion criteria

Exclusion Criteria:

  • History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye.
  • Subfoveal fibrosis or scarring >50% of the total lesion, or atrophy in the study eye, confirmed by central reading center.
  • Choroidal neovascularization (CNV) in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia that would compromise vision in the study eye, confirmed by central reading center.
  • Any concurrent intraocular condition in the study eye (e.g., cataract or glaucoma) that, in the opinion of the Investigator, would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of the study results.
  • Active intraocular inflammation (grade trace or above) in the study eye.
  • History of rhegmatogenous retinal detachment or treatment for retinal detachment or macular hole (stage 3 or 4) in the study eye.
  • History of idiopathic or -associated uveitis in either eye.
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery in the study eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    440 ug, single dose

    EYP-1901 440 ug, single dose

    Drug: EYP-1901

  • Experimental
    2060 ug, single dose

    EYP-1901 2060 ug, single dose

    Drug: EYP-1901

  • Experimental
    3090 ug, single dose

    EYP-1901 3090 ug, single dose

    Drug: EYP-1901

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of ocular (study eye) and systemic treatment emergent adverse events (TEAEs)

    Number of ocular (study eye) and systemic TEAEs during the treatment period - Intent-to-Treat (ITT) Population

    Time frame: Week 48

Secondary outcomes

  1. Change in best corrected visual acuity (BCVA) by EDTRS

    Mean change from Baseline in BCVA in the Study Eye

    Time frame: Baseline, Week 48

  2. Mean change in central subfield thickness (CST)

    Mean change from Baseline in CST measured in microns by Spectral-domain - optical coherence tomography (OCT) assessments by a study-certified OCT technician in the study eye

    Time frame: Baseline, Week 48

07

Study locations

11 sites
  • EyePoint Investigational Site
    Phoenix, Arizona 85053, United States
  • EyePoint Investigational Site
    Beverly Hills, California 90211, United States
  • EyePoint Investigative Site
    Mountain View, California 94040, United States
  • EyePoint Investigational Site
    Oxnard, California 93036, United States
  • EyePoint Investigational Site
    Melbourne, Florida 32901, United States
  • EyePoint Investigational Site
    Saint Petersburg, Florida 33711, United States
  • EyePoint Investigational Site
    Springfield, Massachusetts 01107, United States
  • EyePoint Investigative Site
    Asheville, North Carolina 28803, United States
  • EyePoint Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • EyePoint Investigational Site
    Abilene, Texas 79606, United States
  • EyePoint Investigational Site
    Austin, Texas 78705, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in May 2022, 15 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 15 months is close to that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2021
First posted
Feb 10, 2021
StartActual
Jan 20, 2021
Primary completionActual
May 11, 2022
CompletionActual
May 11, 2022
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04747197
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
Jan 20, 2021
Primary completion
May 11, 2022
Completion
May 11, 2022
Last update
Jul 19, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion